GN
GNLKQ.US Genelink Inc
- Market cap
- USD 10.6K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2013.
Is GNLKQ.US undervalued?
Graham numberThe Graham number of Genelink Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genelink Inc fundamental analysis
No fundamental analysis for Genelink Inc yet.
Genelink Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genelink Inc
GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was incorporated in 1994 and is based in Orlando, Florida.
Full company profileGenelink Inc financial statements
2013 annualized: Fiscal year 2013 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2013, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genelink Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 128K | 305K | 397K | 176K | 97.7K | 6.38M | 8.56M | 7.84M | 4.68M | 2.14M | 1.76M |
| Gross Profit | 63.7K | 213K | 168K | 110K | 26.9K | 4.56M | 4.91M | 4.98M | 2.95M | 465K | 632K |
| Operating Income | -1.14M | -2.11M | -1.28M | -791K | -1.27M | -2.23M | -2.46M | -2.40M | -3.57M | -3.47M | -1.60M |
| EBITDA | -1.12M | -2.09M | -1.24M | -682K | -1.50M | -2.23M | -2.46M | -2.24M | -3.43M | -2.51M | -1.40M |
| Net Income | -1.22M | -2.11M | -1.05M | -585K | -1.56M | -2.60M | -2.72M | -2.63M | -3.83M | -3.05M | -1.62M |
| EPS | -0.05 | -0.07 | -0.03 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 1.21M | 565K | 445K | 548K | 1.38M | 2.55M | 1.88M | 1.72M | 2.78M | 1.45M | 1.28M |
| Total Liabilities | 471K | 765K | 1.06M | 1.41M | 1.19M | 2.49M | 2.62M | 2.51M | 4.26M | 4.12M | 4.49M |
| Shareholders' Equity | 740K | -199K | -613K | -859K | 193K | 52.2K | -740K | -790K | -1.48M | -2.66M | -3.20M |
| Cash & Short-term Investments | 746K | 156K | 15.3K | 150K | 972K | 435K | 197K | 429K | 741K | 158K | 128K |
| Total Debt | 33.0K | 214K | 27.9K | 316K | 506K | 60.3K | 36.1K | 27.5K | - | - | 1.19M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.03M | -1.26M | -321K | -297K | -705K | -1.45M | -2.55M | -1.34M | -2.90M | -2.38M | -489K |
| Capital Expenditure | 10.0K | 37.9K | 118K | 42.6K | 90.8K | 281K | 121K | 124K | 41.3K | 242K | 0.00 |
| Free Cash Flow | -1.04M | -1.29M | -439K | -339K | -796K | -1.73M | -2.67M | -1.46M | -2.94M | -2.63M | -489K |
| Ratios | |||||||||||
| ROE | -164.9% | - | - | - | -807.1% | -4,983.4% | - | - | - | - | - |
| ROA | -100.8% | -374.1% | -236.5% | -106.6% | -112.8% | -102.3% | -144.4% | -153.1% | -137.8% | -209.8% | -126.5% |
| Net Profit Margin | -952.5% | -694.1% | -265.3% | -332.8% | -1,596.6% | -40.8% | -31.7% | -33.6% | -81.8% | -142.9% | -92.5% |
| Debt to Equity | 0.04x | - | - | - | 2.62x | 1.15x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genelink Inc dividends
Genelink Inc has not paid dividends in the last 9 fiscal years.
Who owns Genelink Inc
Ownership data of Genelink Inc is not available yet.
Genelink Inc company profile
- Company name
- Genelink Inc
- Ticker
- GNLKQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 8240 Exchange Drive, Orlando, FL, United States, 32809
- Phone
- 407-680-1150
- Website
- genelinkbio.com
About Genelink Inc
GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was incorporated in 1994 and is based in Orlando, Florida.
Genelink Inc management
2- Dr. Bernard L. Kasten Jr., Ph.D., M.D.Executive Chairman, Chief Executive Officer, President and Member of Scientific Advisory Board · born 1946
- Dr. Robert P. RicciardiFounder, Chief Science Officer, Treasurer, Secretary, Director & Member of Scientific Advisory Board · born 1947